ClinicalTrials.gg
RecruitingNCT06535815KetoNiFastUpdated Aug 6, 2024

KetoNiFast: Cyclic Enteral Daytime Feeding With Ketogenic Nighttime Fasting

An interventional study of Cyclic enteral feeding with nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate) in Nutrition, Muscle Loss and Inflammatory Response, sponsored by University Hospital of Cologne. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by University Hospital of Cologne · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled Sep 2023, registered Jul 2024).
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Muscular Atrophy with a site in Germany — 7 open to participants now, 8 under way, 1 of them phase 3. Muscular Atrophy · Germany.

Planned enrollment
11th of 21
130 · median 130
Started
2023
with 4 others
No phase
16 of 23
7 open now
Registered
19th of 23
by date

Among the 23 studies in Muscular Atrophy with a site in Germany, this one is the 11th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2023, is one of 16 with no phase, and was the 19th registered.

Muscular Atrophy

413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.

Browse Muscular Atrophy studies →

Open to participants now

7 of the 23 studies in Muscular Atrophy with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Muscular Atrophy with a site in Germany, or all of them as a file.
02

Study summary

A physiological human nutrition includes circadian feeding and nighttime fasting during sleep. There is increasing evidence, that this natural fasting episode over nighttime majorly contributes to repair processes of the human body. So far, intensive care patients are normally enterally fed continuously, so that there is no circadian nutrition and no nighttime fasting. An enteral nutrition for 12 hours followed by a fasting period of 12 hours supported by exogenous ketone salts potentially improves the reconstitution of ICU patients compared to ICU patients who are continuously enterally fed.

Read the detailed description

There is increasing evidence that a circadian rhythm of feeding (cyclic feeding) could be beneficial for critical ill patients. Cyclic feeding and fasting are assumed to have positive effects on the gut microbiome resulting in optimization of host responses to gastrointestinal pathogens. Another positive effect of cyclic feeding potentially results from activation of a "fasting response", inducing repair pathways such as ketogenesis, mitochondrial biogenesis, anti-inflammatory pathways, antioxidant defenses and autophagy processes. The activation of these repair pathways could diminish cellular stress and promote cellular recovery in critical ill patients. A randomized controlled trial by van Dyck et al. could show that fasting-mimicking intervals of 12 hours are sufficient to generate a metabolic fasting response without risking a caloric deficit. This fasting response can be enhanced by additional supplementation of exogenous ketones. A cyclic enteral nutrition with 12 hours of daytime feeding and 12 hours of ketogenic nighttime fasting compared to a continuous enteral feeding for 24 hours can potentially improve the reconstitution of critically ill Intensive Care patients. This improved reconstitution can be measured by maintenance of muscle mass (measured by ultrasound of the musculus rectus femoris), urea/creatinine ration, length of ventilation, length of ICU and hospital stay, 30-day mortality, ICU mobility scale.

03

Conditions studied

  • Nutrition
  • Muscle Loss
  • Inflammatory Response

Browse trials for

Keywords

  • Ketogenic diet
  • ketogenic fasting
  • cyclic enteral nutrition
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • written to participate in this study
  • admission to ICU
  • enteral nutrition

Exclusion criteria

Exclusion Criteria:

  • Severe liver dysfunction / liver failure ( >7 points / category B)
  • Severe kidney dysfunction (KDIGO stage 3)
  • Total pancreatectomy / insulin dependent diabetes mellitus (IDDM)
  • Pregnancy / lactation
  • concentration \< 80g/l
  • Severe metabolic disorders / severe diseases
  • metabolic or respiratory acidosis
  • Dysfunction of mitochondrial transport of fatty acids
  • Dysfunction of oxidation of fatty acids
  • Dysfunction of gluconeogenesis, production and reduction of ketones
  • Intermittent Porphyria
  • Severe cardiac arrhythmias / cardiomyopathy
  • against enteral nutrition
  • Lack of
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Active comparator
    Interventional: Cyclic enteral nutrition with ketogenic nighttime fasting

    Interventional group: 12 hours of enteral feeding (as per patients´individual calorimetric requirements measured by indirect calorimetry) followed by a fasting period of 12 hours supported by the supplementation of exogenous ketone salts.

    Other: Cyclic enteral feeding with nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)

  • No intervention
    Control: Conventional continuous enteral nutrition

    Control group Continuous enteral nutrition for 24 hours (as per patients´ individual caloric requirements defined by indirect calorimetry).

Interventions

  • OtherCyclic enteral feeding with nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)

    12 hours of enteral feeding (as per patients´individual calorimetric requirements measured by indirect calorimetry) followed by a fasting period of 12 hours supported by the supplementation of exogenous ketone salts.

    Also known as: cyclic nutrition with nighttime fasting and exogenous ß-hydroxybutyrate supplementation

06

What researchers measure

Primary outcomes

  1. Loss of muscle mass

    Loss of muscle mass via Ultrasound of M. rectus femoris of a predefined leg

    Time frame: From date of randomization until the date of ICU discharge up to 1 month

  2. Progress of urea / creatinine ratio

    Urea / creatinine ratio in the patients´ blood

    Time frame: From date of randomization until the date of ICU discharge up to 1 month

Secondary outcomes

  1. Length of invasive and noninvasive ventilation

    Length of invasive and noninvasive ventilation

    Time frame: From date of randomization until the date of ICU discharge up to 1 month

  2. Length of ICU and hospital stay

    Length of ICU and hospital stay

    Time frame: From date of randomization until the date of hospital discharge up to 6 months

  3. 30 day mortality on day 30

    30 day mortality on day 30

    Time frame: From date of randomization 30 days

  4. ICU mobility scale on discharge

    ICU mobility scale (lowest score 0, highest score 10)

    Time frame: From date of randomization until the date of ICU discharge up to 1 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2025, 27 months after the start.

Of 170 non-industry interventional studies with no phase under Muscular Atrophy, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 27 months is above that.

Counting every sponsor, half of 176 studies reached it within 21 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2024
First posted
Aug 2, 2024
StartActual
Sep 1, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Mar 1, 2026
Last update
Aug 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06535815
Lead sponsor
University Hospital of Cologne
Responsible party
Sandra Emily Stoll (Dr., Assistant Professor, University Hospital of Cologne) — Principal investigator
First posted
Aug 2, 2024
Start date
Sep 1, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Aug 6, 2024

Study contacts

Sandra E Stoll, MD, assProf.
Contact
sandraemilystoll@googlemail.com
+49221478 ext. 82054
Fabian Dusse, PD, MD
Contact
fabian.dusse@uk-koeln.de
+49221478 ext. 40806
Bernd W Böttiger, Prof
study director · University Hospital Cologne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion